Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74.4M
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
20.4M
-
Shares change
-
+4.08M
-
Total reported value, excl. options
-
$62.8M
-
Value change
-
+$12.1M
-
Put/Call ratio
-
5.58
-
Number of buys
-
33
-
Number of sells
-
-14
-
Price
-
$3.08
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q1 2021
56 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock as of Q1 2021.
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.4M shares
of 74.4M outstanding shares and own 27.42% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (8.05M shares), ADAMS STREET PARTNERS LLC (3.28M shares), BVF INC/IL (3.23M shares), VANGUARD GROUP INC (1M shares), CHI Advisors LLC (679K shares), RENAISSANCE TECHNOLOGIES LLC (663K shares), DIMENSIONAL FUND ADVISORS LP (417K shares), TWO SIGMA INVESTMENTS, LP (349K shares), Bank Julius Baer & Co. Ltd, Zurich (337K shares), and Stonepine Capital Management, LLC (316K shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.